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 Abstract 
Bone marrow derived mesenchymal stromal cells (BM-MSCs) have been shown to have 
significant therapeutic effects in experimental models of pneumonia and lung injury.  The 
current study examined the roles of the toll like receptor 4 (TLR4) and protease activated 
receptor 1 (PAR1) pathways on MSC survival and therapeutic activity in a murine model of 
pneumonia.  MSCs from TLR4 -/- and R41Q-PAR1 mutated mice were isolated to test the 
effect of mutating these specific pathways on MSC survival when exposed to cytotoxic 
stimuli in vitro.  An E. coli pneumonia model was utilized to assess the effect of these 
specific pathways on MSC therapeutic activity in vivo.  Our results showed that mutation of 
either the TLR4 or PAR1 pathways in MSCs impaired cell survival under conditions of 
inflammatory stress in vitro, and eliminated their therapeutic efficacy in vivo.  Also, 
stimulation of the TLR4 pathway on MSCs led to secretion of low levels of prothrombin by 
MSCs, while disrupting the TLR4 pathway impaired canonical signaling through PAR1 in 
response to thrombin.  Therefore, this study demonstrates that both TLR4 and PAR1 are 
required for MSC survival under inflammatory conditions in vitro and therapeutic capacity in 
vivo, and that the TLR4 pathway regulates signaling through PAR1 on MSCs.   
  
  
Keywords: mesenchymal stem cells, lung injury, pneumonia, protease-activated receptor, 
toll-like receptor 
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 Introduction 
  
Bone marrow mesenchymal stromal cells (BM-MSCs) make up the supportive environment 
for hematopoietic stem cells and have the capacity to differentiate into bone, fat and 
cartilage.  MSCs have been extensively studied as a potential therapy for lung injury and 
sepsis, and have been shown to have several properties that facilitate recovery from lung 
infection and injury such as immunomodulation, secretion of reparative growth factors, and 
augmentation of host defense to infection [1-11].  Based on these promising pre-clinical 
data, efforts have begun to translate MSCs to patients with lung injury [12,13].  However, 
further investigation is needed to determine how MSC survival is regulated in an 
inflammatory environment in order to optimize therapeutic capacity, since prior work has 
demonstrated non-viable MSCs exert no protective effect [2].   
  
The goal of this study was to investigate the role of the toll like receptor 4 (TLR4) and 
protease activated receptor 1 (PAR1) pathways on the therapeutic capacity of MSCs in an 
experimental model of gram-negative bacterial pneumonia.  These particular pathways were 
chosen as the focus of investigation given the principal role of TLR4 and PAR1 in 
inflammation and coagulation, respectively, in response to infectious stimuli.  Furthermore, 
since inflammation and coagulation, in response to infection, are often geographically 
coupled within the host, we hypothesized that TLR4 and PAR1 would be co-regulated on 
MSCs.  There have been published reports linking different PARs and TLRs in various 
experimental models, but the TLR4-PAR1 axis on MSCs has not been reported on to date 
[14-20].  There was a particular focus on understanding how these pathways regulate MSC 
survival under inflammatory conditions.   
  
TLRs are expressed by MSCs and have been shown to regulate a range of functions 
including migration and immunomodulation, as well as cell survival [21-29].  The role of 
TLR4, in particular, was studied since it is the primary TLR responsible for recognizing LPS 
on gram-negative bacteria.  In order to investigate this pathway, MSCs from TLR4 
-/- mice were isolated and tested in both an in vivo infection model as well as in vitro assays 
of cell death.   
  
PARs are G-protein coupled receptors that are cleaved predominantly by coagulation based 
serine proteases.  PAR1 is classically cleaved by thrombin near the N-terminus of the 
extracellular tail at residue 41, leaving a self-tethered ligand that binds to the active site of 
the receptor.  The role of PAR1 on MSC survival and therapeutic activity has been minimally 
investigated to date [30, 31].  In the current study, the PAR1 pathwaywas interrogated in vivo 
and in vitro using a combination of genetically modified cells (MSCs from R41Q-PAR1 
mutated mice) as well as pharmacological agents specific for PAR1 [32].  PAR1 can be 
cleaved by several enzymes, however, as mentioned, thrombin cleaves specifically at 
residue 41 [33].  The use of the genetically modified R41Q-PAR1 mutant MSCs allowed for 
specific analysis of the role of thrombin cleavage of PAR1 on MSC survival and activity. 
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Since MSCs are reparative in response to inflammatory stimuli and since the activation of 
inflammation and coagulation are often co-regulated, our hypotheses were that both TLR4 
and PAR1 would be required for MSC survival and that TLR4 and PAR1 signaling would be 
coupled.  Our results substantiated these hypotheses by showing that both TLR4 and PAR1 
mediate MSC survival and therapeutic capacity, and that TLR4 stimulation controls secretion 
of prothrombin as well as PAR1 signaling in MSCs.      
Methods 
  
Isolation and culture of bone marrow derived mesenchymal stem cells 
  
MSCs were isolated from WT, TLR4 -/-, and R41Q-PAR1 mutated mice as described before.  
Characterization was done as previously described to determine if cells met minimal, 
essential criteria for MSCs (see supplementary material for differentiation assays and 
flow cytometry methods) [2,5,34].  
  
MSCs were cultured in -MEM media (Gibco, catalog #12561) supplemented with 15% FBS 
(Gibco, catalog #12662-029) and 1% Pen-Strep and L-Glutamine.  Cells were split at 70-
80% confluency and seeded into T-150cm2 flasks at approximately 150,000 cells per flask.  
Media was changed every 3-4 days and cells were split every 6-7 days.  MSCs were used 
for experiments between passages 5-10.   
  
In vivo E. coli pneumonia model and experimental design 
  
All mice used for these experiments were male C57BL/6J (Jackson Labs) between the ages 
of 10-15 weeks of age.  All experiments were approved by the University of California, San 
Diego (UCSD) Institutional Animal Care and Use Committee (IACUC), and mice were 
housed in a UCSD facility approved by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) before and during the experiment.  The survival 
experiments, using death as the endpoint, were approved by the UCSD IACUC.  In non-
survival experiments, mice were euthanized with CO2 inhalation and then cervical 
dislocation.   
  
E. coli K1 strain (originally isolated from the blood of a patient with biliary sepsis; provided by 
Xiao Su, MD, PhD, Pasteur Institute-Shanghai) was used for all in vivo experiments, and the 
experimental design is as we have previously described [2,5].  To briefly summarize, E. coli 
was grown in LB broth for 16-17 h overnight at 37oC, and the following morning the E. coli 
bacteria were washed and diluted first to OD = 1 at 600 nM.  The E. coli was then diluted to 
1 x 106 colony-forming units (cfu) in 25 μl of PBS.  Subsequently, mice were anesthetized 
with ketamine and xylazine (90 mg/kg and 10 mg/kg i.p., respectively), and placed on an 
intubating stand with a fiberoptic light over their neck to transilluminate the trachea.  Then, 
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the mouth and oropharynx were opened with a forceps, and the E. coli instillate (1 x 106 
cfu/25 l PBS) was injected through the vocal cords into the trachea.  The mice were then 
recovered until they regained activity.  After 4-5 h, mice were reanesthetized at half the usual 
dose of ketamine/xylazine and either MSC or PBS (control) was administered intratracheally 
(IT) using the method outlined above.  MSCs were harvested and resuspended at a 
concentration of 500,000 cells / 40 l PBS; PBS was given at a volume of 40 l.  Mice were 
then followed for 12 – 48 hrs before experiments were terminated to collect samples for 
analysis.   
  
Bronchoalveolar lavage (BAL) analyses 
  
Mice were euthanized at predetermined time points (12-24 hr), and a 20-gauge luer stub 
adapter was inserted into the trachea.  Then, 1 ml of cold PBS without Ca++ or Mg++ was 
flushed through the luer adapter into the trachea and lungs and then aspirated back into the 
syringe.  This was done a total of 3 times.  Cell counts were measured using a cell counter 
(Invitrogen), and a differential was determined using a cytospin to pellet cells on a slide, 
which was then stained with hematoxylin and eosin.  The supernatant from the BAL fluid was 
collected and analyzed for total protein using the BCA method (Pierce) as well as for 
macrophage inflammatory protein-2 (MIP-2) measurement using an ELISA (R & D, catalog 
#MM200).  MIP-2 was chosen since it is an important neutrophil chemokine and correlates 
with neutrophil recruitment to the lung.  Supernatants were stored at  
-80oC until analysis.   
  
Measurement of lung injury, histology and bacterial burden 
  
Lung injury was quantified by calculating extravascular lung water (ELW) using the method 
outlined in our previous studies [2,5].  For histological analysis, mice were euthanized, a luer 
adapter was placed into the trachea, and 1.5 ml of a 10% zinc formalin solution was gently 
instilled into the lungs for fixation and inflation, ensuring a distention pressure less than 25 
cm H2O, in order to avoid injury.  The trachea was tied off with a suture, and the lungs were 
removed from the thoracic cavity and immersed in a vial of10% zinc formalin.  The lungs 
were then processed and sectioned in a standard manner and stained with hematoxylin and 
eosin.   
  
In order to measure the bacterial burden, lungs were removed from the thoracic cavity, 
immersed in 1 ml of PBS, and homogenized thoroughly.  Dilutions of the solution were made 
and plated on LB Agar plate overnight at 37oC.  Colonies were counted the next morning.   
  
Measurement of Caspase 3/7 Activity 
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Cell death was assessed using a plate-based assay that measures caspase 3/7 activity 
(Promega, catalog #G7790).  MSCs were plated at approximately 10,000 cells per well and 
allowed to grow to confluence overnight.  Then, MSCs were serum starved in 0.5% FBS the 
next night to prepare them for induction for cell death.  Cell death was induced with a 
combination of TNF- (100 ng/ml) and cycloheximide (20 g/ml) for approximately 4 h.  This 
combination of compounds was chosen as it resulted in the most reproducible quantity of 
cell death for MSCs, and it has been published as an in vitro method to model cell death in 
an inflammatory environment [35, 36].  After 4 h of exposure, the caspase 3/7-substrate was 
added to the wells and the fluorescence was measured at different time points using a plate 
reader.   
  
Assessment of MSC barrier resistance 
  
Using an electrical impedance system (ACEA biosciences, iCelligence) to assess barrier 
resistance of monolayer of MSCs, we determinedthe sensitivity of different populations of 
MSCs to cytotoxic stimuli (TNF-α and cycloheximide).  MSCs were plated at a density of 
30,000 cells per well (8 well chamber) and allowed to grow to confluency.  Cells were then 
serum starved overnight in 0.5% FBS and then were exposed to TNF-α (100 ng/ml) and 
cycloheximide (20 g/ml).  Barrier resistance was then continuously monitored in real-time 
with the iCelligence device.  While MSCs do not classically form monolayers in the alveolar 
space in vivo, this system provided a unique method in which to monitor cytotoxicity in real 
time over the course of several hours to days.   
  
RNA isolation and Reverse Transcriptase-PCR  
  
RNA was isolated from MSCs using standard procedures (Qiagen Mini-Kit), and purity and 
quantity were assessed using a Nano-drop system.  RNA was then reverse transcribed into 
cDNA (Applied Biosystems), and cDNA was amplified using standard PCR procedure 
(Applied Biosystems, Eppendorf Thermocycler).  The resulting product was then loaded and 
run on a 1% agarose gel, stained with ethidium bromide, and developed using a standard 
gel imaging system (Bio-Rad).  Primer sequences for reverse-transcriptase PCR for PAR1 
and GAPDH gene expression were as follows:  
  
PAR1 forward: CCTATGAGCCAGCCAGAATC, PAR1 reverse: 
TAGACTGCCCTACCCTCCAG (GenBank: BC031516.1, PAR1 forward from 131-150, PAR1 
reverse from 173-192).   
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GAPDH forward: AACTTTGGCATTGTGGAAGG, GAPDH reverse: 
ACACATTGGGGGTAGGAACA (GenBank:GU214026.1, GAPDH forward from 564-583, 
GAPDH reverse from 767-786).   
  
For the detection of prothrombin gene expression in MSCs, cells were stimulated with a 
range of LPS concentrations (0.1 – 1 M, Sigma, catalog #L6529) for 6 h, and then cells 
were lysed for RNA extraction and cDNA production as above.  The following primers 
sequences were then used for PCR:  
  
F2 forward: GGACGCTGAGAAGGGTATCG, F2 reverse: CTTGTCTGGCAAACACACGG 
(GenBank: NM_010168.3, F2 forward from 1156-1175, F2 reverse from 1441-1460). 
  
Protein Isolation and Western Blotting 
  
MSCs were lysed and protein isolated using RIPA buffer (ThermoFisher).  The quantity of 
protein in each sample was determined using the BCA method (Pierce, ThermoFisher).  
Approximately 30 μg of protein was mixed with loading buffer and reducing agent and then 
denatured at 90oC for 10 min.  Samples were loaded onto a 4-12% Bis-Tris gel (NuPage, 
Invitrogen) along with a molecular weight marker and run at 120 volts for 60 min.  The gel 
was transferred to a nitrocellulose membrane, blocked and incubated with primary (Actin, 
Neomarkers, Fremont, CA, catalog #MS-1295-P0; PAR1, Abbiotec, San Diego, CA, catalog 
#251324; Tissue Factor, American Diagnostics, Stamford, CT, catalog #4515) and 
secondary antibodies (LiCor) in standard, sequential fashion.  After appropriate washing with 
PBS-0.1% Tween-20 buffer, the membrane was visualized using a LiCor machine.   
  
For the detection of prothrombin in MSC conditioned media, MSCs were stimulated with LPS 
for 6 h using DMEM:F12 50:50 with no added FBS or phenol red.  The conditioned media 
was then concentrated with a 50-kDa filter (Amicon, Millipore) and subsequently run on a gel 
using standard technique as above.  Prothrombin was detected using a sheeppolyclonal 
antibody (Haematologic Technologies Inc, catalog #PAHFII-S) along with a corresponding 
secondary antibody (LiCor).  The positive control for these studies was recombinant human 
prothrombin (Haematologic Technologies Inc., catalog #HCP-0010).    
  
Signaling Assays 
  
On-Cell Western assays were done using a 96-well black, with clear bottom, plate (Corning) 
to determine intracellular signaling pathways activated by thrombin.  MSCs were plated at 
approximately 10,000 cells per well, allowed to adhere overnight, serum starved in 0.5% 
FBS the next night, and then stimulated with thrombin (Enzyme Research Laboratories, 
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catalog #MIIa) at 5-10 nM for 0 – 120 min.  MSCs were subsequently fixed with 4% 
formaldehyde, permeabilized with 0.1% Triton X-100, and blocked with appropriate buffer 
(LiCor).  MSCs were then incubated with an anti-pERK1/2 (Cell Signaling, rabbit polyclonal, 
catalog #9102) or anti-pAKT antibody (Cell Signaling, rabbit polyclonal, catalog #9271) 
overnight at 4oC, washed, and incubated with the appropriate secondary antibody (LiCor) 
before developing on the LiCor machine.  DRAQ5 (ThermoFisher, catalog #62251) was 
added with the secondary antibody solution to quantify and normalize for the total number of 
cells per well.  
  
A phospho-protein signaling array (Cell Signaling, catalog #7323) was done according to 
manufacturer’s instructions in order to characterize the differences between WT and TLR4 -
/- MSC intracellular pathway activation (see supplementary material for details on 
methods).   
  
ERK1/2 inhibition of MSCs 
  
An ERK1/2 inhibitor, FR180204 (Sigma, catalog #SML0320), was incubated with MSCs in 
tissue culture at a concentration of 5 M for 30-45 minbefore washing and harvesting the 
cells.  MSCs were then administered IT to mice previously injured with E. coli as outlined in 
the experimental design above.  The effect of ERK1/2 inhibition on MSC function was 
ascertained by assessing the therapeutic effect of the MSCs in vivo.   
  
Blockade of PAR1 on Human MSCs with Vorapaxar 
  
Bone marrow derived-human MSCs (Texas A&M) were incubated with vorapaxar (Axon 
Medchem, catalog #1755) 0.3 M for 30 min to block PAR1, and then cells were washed, 
harvested, and administered in vivo to mice using the pneumonia model outlined above.  
Mouse survival was measured to determine the effect of PAR1 blockade on the therapeutic 
value of human MSCs.    
  
Statistical analysis 
  
Survival data was analyzed using a log-rank test, while the majority of the other data 
presented was presented as mean ± SD for each group analyzed.  An unpaired, two sided 
student’s t test was used for most comparisons between two sets of data, however, for sets 
of data with a small sample size (total n < 20) a Mann-Whitney U test was used.  If multiple 
groups of data were compared simultaneously, an ANOVA was used.  A p-value < 0.05 was 
used for statistical significance.   
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Results 
  
Characterization of MSCs 
  
MSCs from WT, TLR4 -/- and R41Q-PAR1 mutated mice were isolated and characterized as 
we have described [2,5].  Both differentiation assays and flow cytometry were done as 
specified by the previously prescribed criteria for defining MSCs [34].  WT and TLR4 -/- 
MSCs demonstrated the ability to differentiate into bone, fat and cartilage, whereas R41Q-
PAR1 mutated MSCs retained the ability to differentiate into bone and fat (Supplementary 
Figure 1A – 1H).  Flow cytometry showed that WT, TLR4 -/- and R41Q-PAR1 mutated 
MSCs met the majority of the specified criteria for MSC cell surface marker expression with 
the exception of CD90 (Supplementary Figure 2A – 2F).  In addition, TLR4 -/- MSCs did 
not show expression of CD105 (Supplementary Figure 2C). 
  
TLR4 -/- MSCs displayed increased susceptibility to cell death 
  
When exposed to cycloheximide and TNF-α, TLR4 -/- MSCs exhibited increased levels of 
cell death compared to WT MSCs as assessed by caspase 3/7 release (Figure 1A).  In 
addition, measurement of transcellular resistance of an MSC monolayer also suggested 
increased cellular toxicity of TLR4 -/- MSCs, as compared to WT MSC, when exposed to 
cycloheximide and TNF-α (Figure 1B, 1C).  Histological analysis of WT and TLR4 -/- MSCs 
qualitatively showed more evidence of disruption of normal cellular architecture and cell 
death in TLR4 -/- MSCs in these assays (Supplementary Figure 3).   
  
A signaling array was done to determine potential pathways involved in the increased 
susceptibility to cell death observed in TLR4 -/- MSCs.  As shown in Supplementary 
Figures 4A – 4D, WT MSCs exhibited qualitatively higher levels of phosphorylated pro-
survival proteins, such as ERK1/2, PRAS40 and p38, when compared to TLR4 -/- MSCs 
under basal and TNF-α stimulated conditions.  Meanwhile, TLR4 -/- MSCs demonstrated 
greater relative phosphorylation of pro-apoptotic proteins such as p53 and Bad when 
exposed to TNF-α.   
  
MSCs lacking TLR4 Confer No Protective Effect In Vivo 
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When TLR4-/- MSCs were administered IT to mice 4 h after IT instillation of E. coli K1, there 
was no evidence of survival benefit, reduction in lung injury, or enhancement of bacterial 
clearance 48 h after infection (Figure 2A – 2C).  Hematoxylin and eosin staining of lung 
sections qualitatively demonstrated no improvement in lung damage in mice treated with 
TLR4 -/- MSCs, supporting the quantitative analysis (Figure 2D).     
  
12-24 h BAL fluid from mice treated with TLR4 -/- MSCs exhibited no reduction in the influx 
of inflammatory cells (predominantly neutrophils), the neutrophil chemokine MIP-2, or the 
total level of protein when compared to PBS treated mice (Figure 2E – 2H).  WT MSC 
treated mice did show an improvement in all of these parameters.     
  
MSCs express PAR1 and TLR4 pathway regulates MSC secretion of prothrombin and 
signaling through PAR1 
  
Given that inflammation and coagulation are coupled during infection and the published 
reports linking TLRs and PARs [14-20], we sought to examine the interaction between the 
TLR4 and PAR1 pathways in MSCs.  Specifically, we studied how stimulation and disruption 
of the TLR4 pathway affects activation and signaling through PAR1, respectively.  We 
postulated that MSCs may be a source of prothrombin themselves, and that this may be 
resulting in an autocrine, pro-survival signaling pathway for MSCs.  This might explain the 
increased susceptibility of R41Q-PAR1 mutated MSCs to cell death as seen in Figure 5A.  
In fact, we found that stimulation of MSCs with LPS led to upregulation of the prothrombin 
gene transcript at 6 h as well as detection of the prothrombin protein in the conditioned 
media of LPS stimulated MSCs at 6 h (Figure 3A, 3B).  The slight difference in the size of 
the prothrombin protein between the positive control (recombinant human prothrombin) and 
experimental conditions (mouse MSC conditioned media) may reflect species and cell 
processing alternations in the prothrombin protein.  We also determined that MSCs do 
express the PAR1 receptor at the gene and protein levels, but that TLR4 stimulation with 
LPS did not seem to lead to significant changes in PAR1 expression (Figure 3C, 3D).  
Furthermore, we found that MSCs express tissue factor as determined by Western blotting 
(Figure 3E), which could provide the scaffolding for factor Xa to cleave the self-generated 
prothrombin into thrombin and thereby lead to PAR1 activation.   
  
In order to investigate the effect of the TLR4 pathway on PAR1 signaling, we compared the 
quantity of ERK1/2 phosphorylation in WT and TLR4 -/- MSCs in response to thrombin 
stimulation.  ERK1/2 is part of the mitogen-activated protein kinase (MAPK) family and is 
classically activated with thrombin cleavage of PAR1 [33].  Stimulation with thrombin only led 
to ERK1/2 phosphorylation in WT MSCs (Figure 3F, 3G), even though both WT and TLR4 -
/- MSCs expressed the PAR1 protein (Figure 3H),.  These data suggest that the TLR4 
pathway at least partly controls stimulation and signaling through PAR1 on MSCs.    
  
Furthermore, since our data demonstrate that both the TLR4 and PAR1 pathways are linked 
to ERK1/2 phosphorylation in MSCs, we carried out experiments with an ERK1/2 inhibitor 
(FR180204) to determine if phosphorylation of this signaling protein is required for MSC 
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derived therapeutic efficacy.  We found that pre-treatment of WT MSCs with FR180204 
negated the therapeutic effect of the cells in vivo as determined by survival, suggesting that 
ERK1/2 phosphorylation is required for MSC activity in vivo (Figure 3I).   
  
Thrombin induces a pro-survival phenotype in MSCs  
  
Given the links between the TLR4 and PAR1 pathways we observed, we further explored 
the effect of thrombin, the principal PAR1 agonist, on MSC survival when cells were exposed 
to inflammatory stimuli in vitro.  Initially, we investigated whether thrombin activated other 
pro-survival pathways such as Akt, but as seen in Figures 4A and 4B, only ERK1/2 was 
rapidly phosphorylated.  This is consistent with previous literature demonstrating that PAR1 
cleavage by thrombin shows biased agonism towards ERK1/2 signaling [33].  Thrombin also 
enhanced MSC barrier resistance, when compared to unstimulated MSCs, as measured by 
transcellular electrical impedance (Figure 4C, 4D).  In addition, thrombin reduced MSC 
death, as assessed by caspase 3/7 release, when cells were exposed to the cytotoxic stimuli 
of TNF- and cycloheximide (Figure 4E).  
  
R41Q-PAR1 mutated MSCs exhibit greater sensitivity to cytotoxic stimuli and diminished 
therapeutic capacity 
  
Since thrombin activation of PAR1 leads to pro-survival signaling and phenotype in MSCs, 
we next examined the effects of mutating PAR1 on MSC survival and therapeutic activity.  
R41Q-PAR1 mutated MSCs exhibited increased susceptibility to cell death from TNF- and 
cycloheximide compared to WT MSCs as measured by caspase 3/7 release (Figure 5A).  
Pre-stimulation of the R41Q-PAR1 mutated MSCs with thrombin receptor activating peptide 
(TRAP) at 10 M for 1 h, which specifically activates PAR1, reduced the amount of capase 
3/7 release compared to unstimulated PAR1-mutated MSCs (Figure 5B).  In addition, we 
showed that R41Q-PAR1 mutated MSCs have impaired ERK1/2 phosphorylation in 
response to thrombin stimulation, which is consistent with mutation of the canonical thrombin 
cleavage site in these cells (Figure 5C).   
  
In order to ascertain the role of thrombin activation of PAR1 on MSCs in vivo we tested the 
ability of the PAR1-mutated MSCs to rescue mice with E. coli pneumonia.  We found that 
R41Q-PAR1 mutated MSCs conferred no beneficial effect in vivo, when using the E. coli 
lung infection model, in terms of survival and bacterial burden at 48 h post-infection (Figure 
5D, 5E).  In contrast, WT MSCs did significantly improve survival and bacterial clearance 
when compared to the PBS control treated group.   
  
To determine whether our findings in mouse MSCs could be extrapolated to human MSCs, 
we used a newer generation, clinically tested PAR1 antagonist, vorapaxar, to block PAR1 
activation on human MSCs (obtained from an NIH repository at Texas A&M School of 
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Medicine, Dr. Darwin Prockop).  Pre-treatment of human MSCs with vorapaxar completely 
eliminated the therapeutic effect of human MSCs in a mouse model of E. coli pneumonia.  
Untreated human MSCs conferred a trend towards improved survival versus PBS treated 
mice, which did not reach a level of statistical significance (p = 0.08).  This finding suggests 
that PAR1 activation on human MSCs is necessary for their therapeutic ability in the E. coli 
pneumonia model (Figure 5F).   
  
  
Discussion 
  
BM-MSCs have been extensively studied in the last decade given their potential promise as 
cell based immunotherapy for a wide range of disease states that are due to dysregulated 
inflammation.  The literature has demonstrated that MSCs have potent, reproducible, 
beneficial effects in acute, inflammatory lung injury due to infection, and these results have 
been attributed to a number of properties of MSCs including immunomodulation, secretion of 
reparative growth factors, and augmentation of host defense mechanisms [1-11].  The 
current study specifically aimed to determine the roles of the TLR4 and PAR1 pathways in a 
gram-negative pneumonia model in mice, and the following results were demonstrated: (a) 
TLR4 and PAR1 are both required for the therapeutic effect of MSCs in vivo; (b) disruption of 
TLR4 and PAR1 signaling lends MSCs more susceptible to cell death under inflammatory 
conditions in vitro; and (c) TLR4 regulates MSC secretion of prothrombin as well as signaling 
through PAR1.  To our knowledge, this is the first study to demonstrate the coupling of TLR4 
and PAR1 signaling on MSCs as well as the secretion of a coagulation factor by MSCs.   
  
Inflammation and coagulation are spatially coupled at the sites of infection as part of the 
host’s response to bacterial pathogens [37-41].  Since we administered MSCs directly into E. 
coli infected lungs in this study, we were particularly interested in the roles of TLR4 and 
PAR1 on the therapeutic effects of MSCs and the potential crosstalk between these 
pathways.  TLR4 has been shown to regulate several MSC functions including migration, 
differentiation, and immunomodulation [21-29].  In this study, we used TLR4-/- MSCs to 
investigate the role of the TLR4 pathway on cell survival under inflammatory conditions.  
Using a combination of TNF- and cycloheximide to simulate the cytotoxic milieu of the 
alveolar space in pneumonia, we were able to demonstrate that TLR4-/- MSCs were more 
susceptible to cell death than WT MSCs.  This was determined by measuring caspase 3/7 
activity in the cells as well as by assessing the barrier resistance of MSC monolayers.  
Mechanistically, this may be due to the finding that the signaling profile of TLR4 -/- MSCs 
has less activation of pro-survival pathways such as ERK1/2, p38, and PRAS40 and greater 
activation of pro-apoptotic pathways such as p53 and Bad, when compared to WT MSCs.  In 
vivo, TLR4 -/- MSCs exerted no therapeutic effect in terms of survival, lung injury or bacterial 
clearance.  Of note, the characterization of the different lines of MSCs used in this study 
demonstrated that  TLR4 -/- MSCs did not express detectable CD105.  This finding may also 
impact the therapeutic capacity of TLR4 -/- MSCs, since CD105 is known to play a role in 
transforming growth factor-beta (TGF-) signaling, immunomodulation and differentiation. 
[42,43] 
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PCR and Western blotting confirmed that MSCs express PAR1, and stimulation with 
thrombin led to rapid activation of the pro-survival signaling protein ERK1/2, reduction in cell 
death when exposed to cytotoxic stimuli, and enhancement in barrier resistance.  In order to 
specifically ascertain the effect of thrombin cleavage of PAR1 on MSC survival and function, 
we utilized MSCs derived from R41Q-PAR1 mutant mice generated by our group.  PAR1 
mutated MSCs exhibited defective phosphorylation of ERK1/2 in response to thrombin (as 
expected), and an increased susceptibility to cell death upon exposure to cytotoxic stimuli 
that was reduced by TRAP pre-stimulation.  In vivo, R41Q-PAR1 mutated MSCs showed no 
therapeutic properties in terms of survival or bacterial clearance suggesting that thrombin 
cleavage of PAR1 is required for MSC derived protection in bacterial pneumonia.  The 
importance of PAR1 on the activity of MSCs was extended to human MSCs in our study by 
the use of the clinically tested PAR1 antagonist, vorapaxar.  While vorapaxar will block 
PAR1 activation and signaling non-selectively, the finding that vorapaxar treated human 
MSCs have no therapeutic activity in vivo provides some evidence that PAR1 is required for 
human MSC derived protection as well.  Of note, the therapeutic effect seen with untreated 
human MSCs was not as robust as seen with mouse MSCs as the difference in survival 
between human MSC and PBS treated mice did not reach a level of statistical significance.  
This finding may be due to species differences that lend human MSCs less effective in a 
mouse experimental model.     
  
The finding that PAR1 mutated MSCs were more susceptible to TNF- and cycloheximide 
induced cell death, when compared to WT MSCs, despite the absence of exogenous 
thrombin was the impetus for postulating that MSCs may be secreting prothrombin 
themselves.  And, in fact, our data demonstrate that LPS stimulated MSCs do express and 
secrete low levels of prothrombin.  Other pro-inflammatory stimuli such as TNF- also led to 
detectable levels of prothrombin in the conditioned media (data not shown).  The relative 
contributions of self-generated versus exogenous prothrombin on MSC signaling and 
survival during infection in an in vivo system are unclear.  Nonetheless, this finding provides 
a connection between the TLR4 and PAR1 pathways in MSCs.  Furthermore, the finding that 
MSCs express tissue factor as demonstrated by our data and others [44] provides a platform 
on which MSCs can bring factor Xa in close proximity to the cell membrane in order to 
cleave prothrombin into thrombin and thereby activate PAR1.   
  
In addition to the above described link between TLR4 and PAR1 on MSCs, TLR4 -/- MSCs 
did not display activation of ERK1/2 in response to thrombin stimulation, suggesting that 
disrupting the TLR4 pathway impairs PAR1 signaling. Therefore, PAR1 activation and 
signaling in MSCs is directly coupled to and dependent upon an intact TLR4 pathway.  In 
this fashion, MSCs can integrate pro-inflammatory signals such as LPS and thrombin at sites 
of infection in order to maximize survival and thereby produce a sustained reparative effect.  
Furthermore, both pathways are linked to ERK1/2 phosphorylation based on our in vitro 
studies, and therefore we tested how inhibition of ERK1/2 would influence MSC derived 
protection in vivo.  Using FR180204, we were able to show that ERK1/2 phosphorylation is 
required for therapeutic activity in bacterial pneumonia.  Given that ERK1/2 is a central 
regulator of cell survival and migration, this finding is not unexpected but does confirm the 
importance of this particular MAPK pathway in MSCs. 
  
The results of this study may be used to improve the therapeutic capacity of MSCs designed 
for clinical administration.  Testing for ERK1/2 phosphorylation in response to TRAP or 
14 
 
thrombin, for example, would validate the integrity of both the PAR1 and TLR4 pathways in 
MSCs and could serve as a “potency assay” prior to approval for use.   In addition, the TLR4 
and/or PAR1 pathways in MSCs could be pharmacologically activated ex-vivo to initiate pro-
survival signaling and potentially augment MSC-derived therapeutic activity in vivo.   
  
While we focused on MSC survival and signaling as the underlying mechanisms to account 
for the therapeutic effects in vivo, it is possible that TLR4 and PAR1 are also controlling the 
function of MSCs in this experimental system.  This may include secretion of antibacterial, 
growth, and immunomodulatory factors that are important to MSC derived protection.  In 
addition, we concentrated on using one model of gram-negative pneumonia, but we cannot 
definitively extrapolate these findings to other models of pneumonia, particularly ones that 
use gram-positive pathogens.  Gram-positive bacteria usually stimulate other TLRs such as 
TLR2, so further studies will need to be done using these organisms and investigating the 
interaction between TLR2 and PAR1.  Furthermore, we did not test for interactions between 
TLR4 and other PARs, such as PAR2, for which there is some existing literature to show 
cooperative signaling [14-16].  This interaction could occur by direct association between 
TLR4 and PAR2 or possibly indirectly by transactivation of other PARs through PAR1 as is 
well known to occur in other systems [17].   
  
In conclusion, the current study demonstrates that the TLR4-PAR1 axis is important in 
promoting MSC survival under inflammatory conditions, and that disruption of these 
pathways abrogates MSC derived therapeutic effect in experimental pneumonia.  In addition, 
the results show that TLR4 regulates signaling through PAR1 on MSCs, and in particular, 
TLR4 stimulation leads to expression and secretion of prothrombin by MSCs. Continued 
pursuit of these pathways, and their pharmacological or genetic manipulation, may provide a 
fruitful method to enhance the in vivo therapeutic effect of MSCs.  
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 Figure Legends 
  
Figure 1.  TLR4 -/- MSCs show increased susceptibility to cell death when exposed to 
cytotoxic stimuli in vitro.  After exposure to TNF- (100 ng/ml) and cycloheximide (20 
g/ml) (TNF/CHX), TLR4 -/- MSC showed significantly higher caspase 3/7 activity (A) and a 
significant reduction in monolayer resistance (B, C) (panel A, **p < 0.01 WT vs TLR4 -/- 
MSC, n = 6 per group; panel B and C, **p < 0.01 TLR4 -/- MSC + TNF/CHX vs unstim TLR4 
-/- MSC and WT MSC + TNF/CHX, n = 4 per group).  
  
Figure 2.  TLR4 -/- MSCs exhibit no therapeutic effects in the in vivo E. coli pneumonia 
model.  TLR4 -/- MSCs did not improve survival (A), lung edema (B), or bacterial burden (C) 
as compared to PBS treated mice at 48 h (panels A and B, *,  p < 0.05 for WT MSC vs 
PBS and TLR4 -/- MSC groups, respectively; panel C, **, # p < 0.01 for TLR4 -/- MSC vs WT 
MSC and PBS treated groups, respectively; n = 15 – 20 per group).  Lung histology also 
demonstrated that TLR4 -/- MSC treated mice had no appreciable decrease in lung damage 
versus PBS treated mice (D).  BAL at 12 h post-infection demonstrated that TLR4 -/- MSCs 
did not reduce inflammatory cell influx into the alveolar space (panels E and F, *,  p < 0.05 
for WT MSC vs PBS and TLR4 -/- MSC groups, respectively, n = 4 per group).  At 24 h post-
infection, BAL studies showed that TLR4 -/- MSCs did not reduce the levels of the 
inflammatory cytokine, MIP-2, or the albumin concentration (G and H, respectively, *,  p < 
0.05 for WT MSC vs PBS and TLR4 -/- MSC groups, n = 6-9 per group).   
  
Figure 3.  TLR4 stimulation induces prothrombin secretion by MSCs and regulates 
canonical signaling through PAR1.  WT MSCs demonstrated evidence of prothrombin 
gene expression upon stimulation with 100 nM of LPS, which was not seen in TLR4 -/- MSC 
or 3T3 fibroblasts.  Mouse liver cDNA was used as a positive control for prothrombin (A).  
Conditioned media from MSCs stimulated with LPS demonstrated the presence of 
prothrombin protein as detected by Western blotting.  Recombinant human prothrombin was 
used as the positive control for these studies (B).  Reverse transcriptase-PCR demonstrated 
that MSCs expressed the transcript for PAR1 (C), and Western blotting confirmed that MSCs 
expressed the PAR1 protein (D).  There was no appreciable change in PAR1 expression by 
MSCs with LPS stimulation (3T3, mouse embryonic fibroblast cell line; bEND.3, mouse brain 
endothelial cells line used as positive control).  MSCs also were shown to express tissue 
factor by Western blotting (Figure 3E, bEND.3 cell line used as positive control).  Thrombin 
stimulation (10 nM) led to significant ERK1/2 phosphorylation at 5 min in WT MSCs but not 
in TLR4 -/- MSCs (F, G; **p < 0.01 for TLR4 -/- MSCs vs WT MSCs; n = 3 per group per 
time point), despite both WT and TLR4 -/- MSC qualitatively expressing similar amounts of 
PAR1 protein by Western blotting (H).  Using the in vivo model, we determined that inhibition 
of ERK1/2 with FR180204 eliminated the therapeutic efficacy of WT MSCs, suggesting that 
this central signaling pathway is required for MSC derived protection (I, *p < 0.05 for MSC vs 
PBS treated group, n = 18 - 20 per group).   
  
Figure 4.  Thrombin leads to ERK1/2 biased signaling and exerts a pro-survival 
phenotype in MSCs.  Thrombin (IIa) led to phosphorylation of ERK1/2, 5 min after it was 
added to MSCs as seen in panels A and B, but there was no evidence of Akt 
phosphorylation (**p < 0.01 for 5 min phosphorylation versus 0 and 120 min; n = 3 per group 
20 
 
per time point).  Thrombin also increased MSC monolayer barrier resistance under basal 
conditions (C, D; **p < 0.01 for WT + IIa vs Unstim WT MSCs, n = 4 per group).  When 
added 30 min before TNF + CHX, thrombin reduced caspase 3/7 activity in MSCs (E; *p < 
0.05 for IIa + TNF + CHX vs TNF + CHX, n = 5 per group).   
  
Figure 5.  R41Q-PAR1 mutated MSCs demonstrate increased cell death when exposed 
to inflammatory stimuli in vitro and no therapeutic capacity in vivo.  R41Q-PAR1 
mutated MSCs demonstrated increased cell death as measured by caspase 3/7 activity (A, 
**p < 0.01 for R41Q MSCs vs WT MSCs, n = 6 per group).  Pre-treatment of R41Q-PAR1 
mutated MSCs with 10 M of TRAP for 1 h reduced the quantity of cell death (B, **p < 0.01 
for R41Q MSC + TRAP vs R41Q MSC, n = 6 per group).  R41Q-PAR1 mutated MSCs 
exhibited significantly less ERK1/2 phosphorylation than WT MSCs after 5 min of 5 nM of 
thrombin stimulation (C, **p < 0.01 for R41Q MSC vs WT MSC, n = 3 per group).  In vivo, 
R41Q-PAR1 mutated MSCs showed no evidence of therapeutic benefit in terms of 48 h 
survival (D) or whole lung bacterial burden (E) (*, # p < 0.05 for WT MSCs vs PBS and 
R41Q MSCs, respectively, n = 17-22 per group). Human MSCs were incubated with 
vorapaxar at 0.3 M for 30 min and then administered as a treatment in the in vivo model.  
Vorapaxar pre-incubation significantly inhibited the therapeutic capacity of human MSCs in 
vivo when compared to non-pre-treated cells (F, *p < 0.05 for hMSCs vs hMSCs + 
vorapaxar, n = 10-18).    
  
  
Graphical Abstract 
Figure. Schematic demonstrating interaction between TLR4 and PAR1 pathways on MSCs.  
LPS stimulation of TLR4 on MSCs leads to low levels of prothrombin secretion, which can 
then be converted to active thrombin by factor Xa bound by tissue factor (expressed by 
MSCs).  Thrombin can then cleave PAR1 on MSCs and lead to ERK1/2 activation, in the 
presence of an intact TLR4 pathway, and a pro-survival phenotype.   
  
